Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Bialystok, Białystok, Bydgoszcz, Cracow, Elblag, Lodz, Lublin, Radom, Ruda Śląska, Skierniewice, Tarnów, Warsaw, Włocławek, Wrocław, and Wyszkow, PolandSee the 20 sites
- Phase
- Phase 3
Where in Poland
- Specderm Poznanska sp.j.Bialystok, PolandTaking people
- Uniwersytecki Szpital Kliniczny w BialymstokuBialystok, PolandTaking people
- Zdrowie Osteo-MedicBiałystok, PolandTaking people
- Centrum Medyczne Kermed Renata Bijata-Bronisz I Ewa Kowalinska Sp. j.Bydgoszcz, PolandTaking people
- Centrum Medyczne Neuromed Sp. z.o.o.Bydgoszcz, PolandTaking people
- In- Vivo Sp. z o. o.Bydgoszcz, PolandTaking people
- Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne Diab-Endo-Met Sp. z o.o.Cracow, PolandTaking people
- Ambulatorium Sp. z o.o.Elblag, PolandTaking people
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.Lodz, PolandTaking people
- Clinical Best Solutions Sp. z o.o. S.K.Lublin, PolandTaking people
- Prywatny Gabinet Lekarski Centrum Medyczne DiabetikaRadom, PolandTaking people
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.Ruda Śląska, PolandTaking people
- Poradnia AKA-MED Centrum Sp. z o.o.Ruda Śląska, PolandTaking people
- Velocity Nova Sp. z o. o. Velocity SkierniewiceSkierniewice, PolandTaking people
- Centrum Szybkiej Diagnostyki Kardiologicznej "Kardiomed" M. Żabówka E. ŻabówkaTarnów, PolandTaking people
- Medon Clinical Research Sp. z o.o.Warsaw, PolandTaking people
- Międzyleski Szpital Specjalistyczny w WarszawieWarsaw, PolandTaking people
- Kardio LifeWłocławek, PolandTaking people
- Centrum Wsparcia Badań Klinicznych 4 Wojskowego Szpitala Klinicznego we WrocławiuWrocław, PolandTaking people
- Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej W WyszkowieWyszkow, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.